Objective: Epilepsy is one of the most prominent symptoms of tuberous sclerosis complex (TSC), a genetic disorder, and may be related to developmental defects resulting from impaired TSC1 or TSC2 gene function in astrocytes and neurons. Inactivation of the Tsc1 gene driven by a glial-fibrillary acidic protein (GFAP) promoter during embryonic brain development leads to widespread pathologic effects on astrocytes and neurons, culminating in severe, progressive epilepsy in mice (Tsc1 GFAP-Cre mice). However, the developmental timing and cellular specificity relevant to epileptogenesis in this model has not been well defined. The present study evaluates the effect of postnatal Tsc1 gene inactivation on pathologic features of astrocytes and neurons and development of epilepsy. Methods: An inducible Tsc1 knock-out mouse was created utilizing a tamoxifen-driven GFAP-CreER line (Tsc1 GFAP-CreER mice) with TSC1 reduction induced postnatally at 2 and 6 weeks of age, and compared to conventional Tsc1 GFAP-Cre mice with prenatal TSC1 reduction. Western blotting, immunohistochemistry, histology, and video-electroencephalography (EEG) assessed mechanistic target of rapamycin (mTOR) pathway activation, astrogliosis, neuronal organization, and spontaneous seizures, respectively. Results: Tsc1 gene inactivation at 2 weeks of age was sufficient to cause astrogliosis and mild epilepsy in Tsc1 GFAP-CreER mice, but the phenotype was much less severe than that observed with prenatal Tsc1 gene inactivation in Tsc1 GFAP-Cre mice. Both astrocytes and neurons were affected by prenatal and postnatal Tsc1 gene activation to a degree similar to the severity of epilepsy, suggesting that both cellular types may contribute to epileptogenesis. Significance: These findings support a model in which the developmental timing of TSC1 loss dictates the severity of neuronal and glial abnormalities and resulting epilepsy.
Tuberous sclerosis complex (TSC) is a genetic disorder, with epilepsy, intellectual disability, and autism representing common neurologic manifestations.
1,2 TSC is caused by mutation of either the TSC1 or TSC2 genes, leading to activation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway and associated tumor or hamartoma formation in multiple organs. A leading hypothesis about the pathophysiology of epilepsy in TSC has traditionally focused on the role of cortical tuberswhich are focal developmental malformations of the brain-in generating seizures. 3 However, the specific cellular and molecular mechanisms of epileptogenesis in TSC are still incompletely understood. Current treatments for epilepsy and other neurologic manifestations of TSC are primarily symptomatic, but novel targeted therapies, such as with mTORC1 inhibitors, are being explored as potential mechanistically based, disease-modifying treatments for TSC. [4] [5] [6] Further understanding of the cellular and molecular basis of epilepsy in TSC should lead to more effective therapies for this disease and may also have implications for other related disorders involving "mTORopathies."
Pathologic studies of cortical tubers and perituberal regions from TSC patients with intractable epilepsy reveal a variety of cellular and molecular abnormalities. 7, 8 In particular, in addition to a loss of normal cortical lamination, a range of normal and abnormal cell types has been described representing a spectrum of neuronal to glial lineages, including dysmorphic neurons, astrogliosis, microglial activation, and the classic giant cells with immature neuronal and glial features. However, the specific roles and relative contribution of these different cell types to epileptogenesis are unknown and difficult to investigate in human studies.
Animal models have provided some insights into the role of specific cells in epileptogenesis in TSC, using cell-targeted conditional knockout of the Tsc1 or Tsc2 genes. [9] [10] [11] [12] [13] For example, neuron-specific knockout mice, using a synapsin promoter to drive Cre-mediated Tsc1 gene inactivation, have spontaneous seizures, supporting a critical role of neurons in TSC. 14 Although it is perhaps not surprising that neuronal abnormalities promote seizures in TSC, glial cells have been increasingly recognized in modulating brain excitability and potentially promoting epilepsy in general. Other conditional knockout mouse models have attempted to determine the contribution of astrocytes (glia) to epilepsy in TSC, targeting Tsc gene inactivation with a glial fibrillary acidic protein (GFAP) promoter, 15, 16 and identifying a number of abnormal astrocytic mechanisms that promote epileptogenesis in these models. [17] [18] [19] [20] Although GFAP has been largely reported to be "astrocyte-specific," GFAP is also expressed in embryonic neural progenitor cells, and thus prenatal GFAP-driven gene inactivation may have widespread effects on both astrocytes and neurons. 21, 22 In this study, we examined the effect of postnatal Tsc1 gene inactivation on astrocytic and neuronal abnormalities and seizure generation, using an inducible GFAP-Cre mouse model. 22, 23 .
Methods

Animals and tamoxifen administration
Care and use of all mice were conducted according to an animal protocol approved by the Washington University Animal Studies Committee (Institutional Animal Care and Use Committee #A-3381-01) and consistent with National Institutes of Health (NIH) guidelines on the Care and Use of Laboratory Animals, the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines, and the Basel Declaration. In addition, NIH guidelines on Rigor and Reproducibility in Preclinical Research were followed, including use of randomization, blinding, both sexes, and statistical/power analyses. GFAP-CreER mice (obtained from Suzanne Baker's lab) 23 were crossed with Tsc1 flox/flox mice to generate the inducible Tsc1 knockout mice (Tsc1 GFAP-CreER mice). Littermates (Tsc1 f/+; CreER+ or Tsc1 f/f; CreER-) were used as negative controls. For comparison, conventional Tsc1 GFAP-Cre mice were also generated by crossing noninducible GFAP-Cre mice with Tsc1 flox/flox mice. 15 In separate studies, CgGt(Rosa) 26Sor tm6(CAG-ZsGreen1)Hze /J (Rosa-Green; Jackson Laboratory) reporter mice were crossed with GFAP-CreER and GFAP-Cre mice to confirm the cellular localization of Cremediated recombination induced by tamoxifen.
Mice were randomized into tamoxifen or vehicle-treatment groups. Tamoxifen (Sigma, T5648) was dissolved in corn oil (Sigma, C8267) at a concentration of 20 mg/ml. Tamoxifen (9 mg/40 g body weight; i.p.) was administered to mice once a day for five consecutive days at 6 weeks or every other day at 2 weeks of age.
Western blotting
For Western blotting, mice were killed 6 weeks after tamoxifen injection. Neocortex and hippocampus were dissected and sonicated in the lysis buffer (Sigma, P8340). After centrifuging, total proteins were extracted. The concentrations of the total protein extracts were determined by bicinchonincic acid protein assay reagents (Pierce 23223, 23224). Following the normalization of protein concentration, 2X sample buffer (Sigma, S3401) was added to the protein extracts. Equal amounts of protein samples were separated by electrophoresis on BioRad mini-protean TGX gels and transferred to the nitrocellulose membrane. 
Immunohistochemistry/histology
Mice were anesthetized with isoflurane 6 weeks after tamoxifen injection and then subjected to cardiac perfusion of phosphate-buffered saline (PBS) followed by 4% of paraformaldehyde (PFA). The brains were dissected out and immersed in 4% PFA overnight at 4°C. After dehydration in 30% sucrose diluted in PBS (~48 h), the brains were frozen and coronal sections of 40 lm thickness were cut with a microtome (Microm, HM400).
For antibody staining, the brain slices were blocked in solution with 10% normal goat serum (NGS), 1% bovine serum albumin (BSA), and 0.3% triton X-100 in PBS and then incubated in primary antibody (GFAP, Cell Signaling 12389; NeuN, Millipore, MAB 377; S100b, Sigma S2532) diluted in solution of 1% NGS, 1% BSA, and 0.3% triton X-100. The brain slices were then incubated in the secondary antibody (Goat anti-rabbit immunoglobulin G [IgG], Alexa 488-conjugated, Life Technologies A11034; Goat anti-rabbit IgG, Cy3-conjugated, Life Technologies A10520; Goat anti-mouse IgG, Cy3-conjugated A10521) solution (PBS with 1% BSA) for 1 h at room temperature, avoiding light. Images were acquired with a Zeiss LSM PASCAL confocal microscope (Zeiss Thornwood, NY), or with Nanozoomer HT system (Hamamatsu, Bridgewater, NJ). For quantification, images of comparable regions of interest were taken and the ImageJ software was used for the cell number counting and the fluorescent intensity measurement.
For cresyl violet staining, 0.5% cresyl violet acetate was dissolved in warm water with 0.3% glacial acetic acid. The cresyl violet solution was then cooled and filtered. Brain slices were mounted on the glass slides and passed through the following sequence of washes: 95% EtOH 15 min, 70% EtOH 1 min, 50% EtOH 1 min, distilled H 2 O (DH 2 O) 2 min, DH 2 O 1 min, cresyl violet 2 min, 50% EtOH 1 min, 70% acid EtOH 2 min, 95% EtOH 2 min, 95% EtOH a few dips, 100% EtOH 1 min, and Histo-Clear 5 min. Images were acquired with Nanozoomer HT system.
Video-electroencephalography monitoring
Surgery for implanting epidural electrodes for continuous video-electroencephalography (vEEG) recordings were performed at least 1 week after the mice were injected with tamoxifen. Mice were anesthetized with isoflurane and placed in a stereotaxic frame. Epidural screw electrodes were surgically implanted and secured using dental cement for long-term EEG recordings. Four electrodes were placed on the skull: one right and one left central electrodes (1 mm lateral to midline, 2 mm posterior to bregma), one frontal electrode (0.5 mm anterior and 0.5 mm to the right or left of bregma), and one occipital electrode (0.5 mm posterior and 0.5 mm to the right or left lambda). The typical recording montage involved two EEG channels with the right and left central "active" electrodes being compared to either the frontal or occipital "reference" electrode. Video and EEG data were acquired simultaneously with a Stellate video-EEG system (Natus, Pleasanton, CA, U.S.A.). In a blinded analysis, electrographic seizures were identified by their characteristic pattern of discrete periods of rhythmic spike discharges that evolved in frequency and amplitude lasting at least 10 s, typically ending with repetitive burst discharges and voltage suppression. On video analysis, the behavioral correlate to these seizures typically involves head bobbing, rearing with forelimb clonus, and occasional generalized convulsive activity.
Statistical analyses
All statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software). Quantitative differences between groups were analyzed by Student's t-test or one-way analysis of variance (ANOVA) with Tukey's multiple comparisons post hoc tests when comparing one factor over more than two groups. Quantitative data are expressed as mean AE standard error of the mean (SEM). Statistical significance was defined as p < 0.05.
Results
Postnatal injection of tamoxifen decreases TSC1 and increases mTORC1 activity in Tsc1
GFAP-CreER brains Tsc1 GFAP-CreER mice and control littermates were injected with tamoxifen at either 2 weeks or 6 weeks of age. Western blotting was performed 6 weeks after tamoxifen injection to examine the protein levels of mTORC1 pathway components in the brain. For the injection at 2 weeks of age, the protein levels of TSC1 were reduced significantly in both cortex and hippocampus of Tsc1
GFAP-
CreER mice compared with control mice (Fig. 1A,B) , indicating floxed Tsc1 gene recombination mediated by tamoxifen-induced Cre activity. In contrast, TSC2 protein expression was not significantly affected by postnatal TSC1 reduction (Fig. S1 ). mTORC1 activation, as assessed by expression of phosphorylated S6 (pS6), was increased in both the cortex and hippocampus of Tsc1 GFAP-CreER mice 6 weeks after tamoxifen injection (Fig. 1A ,B -normalized to actin; Fig. S1 -normalized to total S6). As additional confirmation of mTORC1 signaling involvement, pP70S6K expression was also increased 6 weeks after tamoxifen injection at 2 weeks of age (Fig. S1 ). For the tamoxifen injection at 6 weeks of age, although we failed to detect a brains by Western blotting, there was a significant increase in pS6 levels in the cortex (Fig. 1C,D) , indicating functional Tsc1 gene inactivation despite an undetectable decrease in protein expression.
Tamoxifen injection induces Cre-recombinase activity in both astrocytes and neurons To confirm the identity of cells targeted by Cre-mediated recombination, we crossed Rosa-Green reporter mice with Tsc1 GFAP-CreER mice. Expression of the GFP reporter gene was detected in both brain astrocytes and neurons at 8 and 12 weeks of age (6 weeks after tamoxifen injections; Figs. 2 and 3) . Some evidence of Cre activity in Tsc1 GFAPCreER mice was observed even without tamoxifen injection ("leakiness"), especially in astrocytes, but Western blotting showed comparable protein levels of both TSC1 and pS6 in the cortex and hippocampus of noninjected Tsc1 GFAP-CreER mice relative to control littermates (Fig. S2) , indicating that the basal Cre expression by itself did not cause any significant functional effect on mTORC1 pathway activation. Furthermore, reporter analysis of noninjected 1-week old Tsc1 GFAP-CreER mice found minimal evidence of Cre activity (Fig. S3) , indicating that the leakiness occurred postnatally, which would simply reinforce the intent of our studies in targeting postnatal Tsc1 gene inactivation. Compared to noninjected controls, tamoxifen injection increased the number of both astrocytes and neurons with reporter gene expression in Tsc1
GFAP-CreER mice, particularly in cortex, although the level of reporter gene expression was not as high as observed in the conventional Tsc1 GFAP-Cre knockout mice (Figs. 2 and 3 ).
Tamoxifen injection increases GFAP-positive astrocytes in Tsc1
GFAP-CreER brains Conventional Tsc1
GFAP-Cre knockout mice show diffuse astrogliosis throughout the brain, manifested by morphologic changes of GFAP-positive astrocytes and an increase in astrocyte number. 15, 24 To examine whether astrogliosis occurs when TSC1 was reduced postnatally, GFAP staining of Tsc1 GFAP-Cre brains was performed 6 weeks following tamoxifen injection. The brains with tamoxifen injection at either 2 or 6 weeks of age showed an increase in GFAP intensity or GFAP-positive cell number (Fig. 4) . However, unlike the widespread astrogliosis found in the conventional Tsc1 GFAP-Cre knockout brains, the increase in GFAP staining of Tsc1 GFAP-CreER brains was confined to certain brain regions, such as piriform cortex, corpus callosum, and cerebral peduncle. We quantified the number of GFAP-positive cells in piriform cortex and the fluorescent intensity in corpus callosum and cerebral peduncle, since the boundaries of the individual astrocytes in the latter two areas are difficult to distinguish. The increase in GFAP staining of the mice injected with tamoxifen at 2 weeks of age was more Tamoxifen injection induces Cre-recombinase activity in astrocytes. (A-E) Confocal images of S100 b staining of astrocytes (red) in the cortex and hippocampus areas of Rosa-Green Cre reporter (green) mice with Tsc1 GFAP-CreER (A, B, D, E) or Tsc1 GFAP-Cre (C). Tamoxifen was injected in Tsc1 + /+ GFAP-CreER or TSC1f/+ GFAP-CreER mice at either 2 weeks (B) or 6 weeks (E) of age. Mice were killed 6 weeks after tamoxifen was injected for the staining. Controls (A, D, Tsc1 + /+ GFAP-CreER or TSC1f/+ GFAP-CreER mice without tamoxifen injection) were killed at 8 weeks of age for the tamoxifen injection at 2-week group and at 12 weeks of age for the tamoxifen injection at 6-week group. The Tsc1 GFAP-Cre conditional knockouts were killed at 8 weeks of age only, as they rarely survive to 12 weeks. GFAP-CreER or TSC1f/+ GFAP-CreER mice at either 2 weeks (B) or 6 weeks (E) of age. Mice were killed 6 weeks after tamoxifen was injected for the staining. Controls (A, D, Tsc1 + /+ GFAP-CreER or TSC1f/+ GFAP-CreER mice without tamoxifen injection) were killed at 8 weeks of age for the tamoxifen injection at 2-week group and at 12 weeks for the tamoxifen injection at 6-week group. The Tsc1 GFAP-Cre CKOs were killed at 8 weeks of age only, as they rarely survive to 12 weeks. (F-M) Quantifications of the percentage of GFP+ neurons (double labeled in yellow) in different areas of brain (*p < 0.05; **p < 0.01; ***p < 0.001, Student's t-test, n = 3 for each group,). Epilepsia ILAE dramatic than those that received tamoxifen at 6 weeks ( Fig. 4B-D,F-H) .
Tsc1
GFAP-CreER mice with postnatal tamoxifen injection show normal brain size, weight, and hippocampal structure Conventional Tsc1
GFAP-Cre knockout mice have enlarged brain sizes and neuronal disorganization in hippocampus. 15, 24 In contrast, postnatal TSC1 reduction did not cause any significant change in brain size and weight or in hippocampal neuronal organization in Tsc1 GFAP-CreER mice (Fig. 5) . In addition, the conventional Tsc1 GFAP-Cre mice all die by 2-3 months of age, 15, 24 whereas the tamoxifen-injected Tsc1 GFAP-CreER mice lived to at least 6 months of age. The exact life span is not known, since Tsc1 GFAP-CreER mice were not followed beyond 6 months of age. GFAP-CreER mice were injected with tamoxifen at 6 weeks of age and killed for staining 6 weeks after tamoxifen injection. NeuN (red) was used as counterstaining. (F-H) Quantification of GFAP+ cell numbers in piriform cortex (F) and GFAP fluorescent intensity in corpus callosum and cerebral peduncle of the mice injected with tamoxifen at 2 weeks (G,H) (***p < 0.001, Student's t-test, n = 4 per group). Epilepsia ILAE Tamoxifen injection at 2 weeks, but not 6 weeks, induces spontaneous seizures in Tsc1 GFAP-CreER mice Essentially 100% of conventional Tsc1 GFAP-Cre knockout mice develop severe, progressive epilepsy, with most mice averaging 10 seizures per day by 2 months of age. 24, 25 In comparison, 6 of 13 monitored Tsc1
GFAP-CreER mice with tamoxifen injection at 2 weeks of age exhibited spontaneous seizures (Fig. 6A,C) , whereas none of the 12 Tsc1 GFAP-CreER mice with tamoxifen injection at 6 weeks exhibited any seizures during the 3-month observation period (Fig. 6B,C) . Among the mice with spontaneous seizures, seizure onset ranged from 6 weeks to 17 weeks of age (Fig. 6D) . One of the mice showed recurrent seizures with the frequency of one or two seizures a week during the 3-month observation period. The remaining mice only had rare (1-2 seizures) during the observation period.
Discussion
In this study, we investigated the effect of postnatal Tsc1 gene inactivation on epilepsy utilizing an inducible GFAPCre line. The primary finding is that postnatal GFAP-driven Tsc1 gene inactivation at 2 weeks of age, but not 6 weeks, is sufficient to cause epilepsy. Although postnatal GFAP expression has been reported to be relatively astrocyte specific, 22, 23 our reporter data indicate that both astrocytes and neurons can be affected by GFAP-driven Cre expression postnatally, thus making it difficult to determine whether the epilepsy phenotype is primarily related to astrocyte or neuronal TSC1 reduction. In any case, the epilepsy phenotype with postnatal TSC1 reduction in inducible Tsc1
GFAP-CreER mice is much milder compared with prenatal TSC1 reduction in Tsc1 GFAP-Cre mice, indicating that embryonic effects of Tsc1 gene inactivation on brain development may be more critical for epileptogenesis in TSC and establishing a temporal window for targeting therapies to prevent or modify epilepsy in TSC.
Conventional (noninducible) GFAP-driven conditional knock-out mice, which exhibit Cre expression during the embryonic period, were initially thought to be relatively specific for targeting gene inactivation to astrocytes. 15, 26 However, the expression of GFAP in embryonic neural progenitor cells results in substantial involvement of derivative neuronal populations, particularly in hippocampus. 21, 27 Thus although conventional Tsc1 GFAP-Cre knockout mice have a number of abnormalities in astrocyte function that likely contribute to epileptogenesis, such as impaired astrocytic glutamate transport and potassium buffering, [17] [18] [19] [20] concurrent involvement of neurons confounds interpretation of the relative contribution of different cell types to epilepsy in these mice. Some studies suggest that postnatal GFAP expression using inducible CreER systems may be more specific for targeting mature astrocytes, 22, 23 but our reporter data indicate that there is still a substantial degree of neuronal involvement with postnatal induction, likely due to persistent expression of GFAP in some neural progenitor cells beyond the embryonic stage. Thus it is still difficult to determine in the Tsc1
GFAP-CreER mice whether the seizures An additional technical issue is that, in contrast to previous reports of the inducible GFAP-CreER line, 22 ,23 a significant amount of baseline "leakiness" of Cre-recombination was detected in our Rosa-Green reporter mice studies, particularly involving both cortical and hippocampal astrocytes, but also a small percentage of neurons in hippocampus. However, this degree of baseline Cre-recombination did not appear to have any appreciable functional effects, as GFAP-CreER mice not treated with tamoxifen did not exhibits changes in TSC1 protein expression or mTORC1 activation as reflected by pS6 expression, or any increase in GFAP expression itself. Furthermore, this leakiness was minimal at 1 week of age, indicating that it occurred postnatally after 1 week, so if anything, this would help reinforce the effects of the targeted postnatal tamoxifen injections. Thus it is reasonable to conclude that postnatal Tsc1 gene inactivation following tamoxifen was primarily responsible for the subsequent seizure generation in the Tsc1 GFAP-CreER mice. However, based on the more severe epilepsy and pathologic phenotype of conventional Tsc1 GFAP-Cre mice, it appears that prenatal effects of Tsc1 gene inactivation on early brain development are more critical for epileptogenesis than postnatal effects in TSC.
Astrogliosis is one of the pathologic features of human tubers mimicked in both Tsc1
GFAP-Cre and Tsc1
GFAP-CreER mice. Although the astrogliosis in Tsc1 GFAP mice is diffuse, these neuropathologic findings in Tsc1
GFAP-CreER mice injected with tamoxifen at 2 weeks were more focal in distribution, although discrete tuber-like abnormalities were not seen. In addition, other cellular features of tubers, such as neuronal disorganization and giant cells, were not seen. Most mouse models of TSC involving embryonic or postnatal Tsc1 or Tsc2 gene inactivation induce relatively diffuse neuropathologic abnormalities, with the possible exception of the focal in utero electroporation model, which shows some tuber-like abnormalities. 10 Although the lack of tuberlike abnormalities could be considered a limitation of this and other TSC mouse models, these models still have significant utility for investigating cellular and molecular mechanisms of TSC that may occur independently of tubers. 28 More refined models combining different spatial and temporal properties of Tsc gene inactivation should continue to lead to more accurate models of human TSC.
Other limitations to this study include the possibility that the methods utilized may not have been optimized to exert maximal effects on Cre-expression and corresponding astrocyte or neuronal phenotypes. In particular, differences in Cre-expression driving pre-and postnatal Tsc1 gene inactivation and the resulting TSC1 protein reduction may confound direct comparisons of phenotypic effects. Additional studies varying the timing or dosing of tamoxifen may reveal additional information about the effects of postnatal TSC1 reduction on epilepsy. A previous study with global postnatal inactivation of Tsc1 demonstrated a severe epilepsy phenotype even in the absence of acute pathologic changes, but the Cre-driver likely affected most cell types throughout the body, limiting interpretation of the specificity of this effect on epilepsy. 29 The use of other Cre-driving promoters, such as Glast or Aldh1L1, may increase astrocyte specificity in attempting to distinguish the relative contribution of astrocytes and neurons to epilepsy. However, the current study illustrates general, practical issues involved in comparing prenatal and postnatal Tsc1 gene inactivation and corresponding effects on brain phenotypes.
Despite these technical caveats and the uncertain contribution of different cell types, a major finding of this study is Table showing the number and percentage of mice exhibiting spontaneous seizures within 3 months after tamoxifen injection at 2 weeks and 6 weeks. (D) Quantification of the average seizure frequency for mice with spontaneous seizures over time after tamoxifen injection at 2 weeks and 6 weeks of age. Epilepsia ILAE the developmental differences of the effect of Tsc1 inactivation in the brain on epileptogenesis. Although postnatal Tsc1 gene inactivation at 2 weeks of age was sufficient to cause epilepsy in about 50% of Tsc1 GFAP-CreER mice, the epilepsy phenotype was much milder compared with prenatal Tsc1 gene inactivation, which leads to progressive epilepsy in 100% of Tsc1 GFAP-Cre mice. 15, 24, 25 Furthermore, postnatal Tsc1 gene inactivation at 6 weeks of age did not induce detectable epilepsy. It is interesting to note that despite the prenatal gene inactivation in Tsc1
GFAP-Cre mice, onset of epilepsy in Tsc1 GFAP-Cre mice is delayed until approximately 3-4 weeks of age, indicating a several-week period of epileptogenesis following Tsc1 gene inactivation. The strong developmental dependence highlights the critical importance of prenatal versus postnatal Tsc1 gene inactivation on epileptogenesis and establishes the temporal window of opportunity for potential disease-modifying interventions. Given that TSC has been viewed as a feasible model disorder for developing anti-epileptogenic therapies for preventing epilepsy, such as with mTOR inhibitors, 5 these findings have direct translational applications for the timing of targeted treatments directed at specific stages of epileptogenesis. Clinical trials of early intervention, such as with vigabatrin, in infants with TSC even before the onset of epilepsy are already underway. 30 Because tubers are formed during prenatal brain development, preventative therapies for epilepsy in TSC may need to be delivered prenatally to be most effective, as suggested by the more severe phenotype of prenatal TSC1 protein reduction in Tsc1 GFAPCre mice. However, as epileptogenesis also occurred to a less severe degree with postnatal TSC1 reduction in Tsc1 GFAPCreER mice, this suggests that even later, postnatal treatment has antiepileptogenic potential. Future experiments in the postnatal Tsc1 GFAP-CreER mice testing the timing of therapeutic interventions, particularly with rapamycin, should help define more specifically the critical window for preventative antiepileptogenic and direct antiseizure effects at different development stages of TSC.
